Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced that the primary endpoint of non-inferiority of A1C levels at six months was met ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE